Q Earnings: $3.4 billion (-17%) FY Revenues: $88.8 billion (+4%) FY Earnings: $14.1 billion (+6%) Comments: Innovative Medicin ...
Johnson & Johnson’s burgeoning depression treatment Spravato eclipsed $1 billion in revenue in 2024 as the pharma’s neuroscience pipeline comes into view.
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...
From breaking news to special features, we're on it! Join the NonStop Local Chord group and always be in the know. WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug ...
nasal spray bottle WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive ...
Credit: Justin Paget via Getty Images. Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major depressive disorder ...
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...
Johnson & Johnson’s Spravato nasal spray has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback